Recent Analysts’ Ratings Changes for Inspire Medical Systems (INSP)

Inspire Medical Systems (NYSE: INSP) has recently received a number of price target changes and ratings updates:

  • 11/6/2019 – Inspire Medical Systems was upgraded by analysts at Berenberg Bank from a “sell” rating to a “hold” rating. They now have a $51.00 price target on the stock, up previously from $46.00.
  • 10/31/2019 – Inspire Medical Systems was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 10/30/2019 – Inspire Medical Systems was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company’s proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States. “
  • 10/29/2019 – Inspire Medical Systems was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $65.00 price target on the stock. According to Zacks, “Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company’s proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States. “
  • 10/23/2019 – Inspire Medical Systems was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company’s proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States. “
  • 10/22/2019 – Inspire Medical Systems was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $61.00 price target on the stock. According to Zacks, “Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company’s proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States. “
  • 10/17/2019 – Inspire Medical Systems was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company’s proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States. “
  • 10/16/2019 – Inspire Medical Systems was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $59.00 price target on the stock. According to Zacks, “Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company’s proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States. “
  • 9/27/2019 – Inspire Medical Systems was given a new $78.00 price target on by analysts at Dougherty & Co. They now have a “buy” rating on the stock.

Shares of INSP traded up $4.31 during mid-day trading on Friday, hitting $64.05. The company’s stock had a trading volume of 407,346 shares, compared to its average volume of 306,413. The firm has a 50-day moving average price of $58.93 and a 200 day moving average price of $60.07. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -42.70 and a beta of 1.22. The company has a debt-to-equity ratio of 0.16, a current ratio of 20.46 and a quick ratio of 20.05. Inspire Medical Systems has a fifty-two week low of $35.43 and a fifty-two week high of $71.71.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.09. The company had revenue of $20.86 million for the quarter, compared to analysts’ expectations of $19.15 million. Inspire Medical Systems had a negative net margin of 40.36% and a negative return on equity of 18.32%. The business’s revenue was up 59.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.22) EPS. As a group, equities analysts anticipate that Inspire Medical Systems will post -1.55 EPS for the current fiscal year.

In other news, CEO Timothy P. Herbert sold 15,000 shares of Inspire Medical Systems stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $65.96, for a total value of $989,400.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Marilyn C. Nelson sold 60,000 shares of Inspire Medical Systems stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $66.71, for a total transaction of $4,002,600.00. Insiders sold a total of 191,790 shares of company stock worth $12,433,812 in the last ninety days. Corporate insiders own 12.10% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Inspire Medical Systems by 293.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 637 shares of the company’s stock worth $39,000 after acquiring an additional 475 shares in the last quarter. Marshall Wace North America L.P. purchased a new position in shares of Inspire Medical Systems in the first quarter worth approximately $45,000. Royal Bank of Canada increased its position in shares of Inspire Medical Systems by 593.3% in the second quarter. Royal Bank of Canada now owns 1,040 shares of the company’s stock worth $63,000 after acquiring an additional 890 shares in the last quarter. Advisory Services Network LLC increased its position in shares of Inspire Medical Systems by 24.6% in the second quarter. Advisory Services Network LLC now owns 1,395 shares of the company’s stock worth $85,000 after acquiring an additional 275 shares in the last quarter. Finally, First Quadrant L P CA purchased a new position in shares of Inspire Medical Systems in the second quarter worth approximately $118,000. 83.05% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Featured Story: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply